VERIMATRIX
31.3.2022 17:47:08 CEST | Business Wire | Press release
Regulatory News:
Verimatrix , (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Capri Healthcare chose Verimatrix App Shield , part of Verimatrix’s threat defense business line, to gain fast and proven defenses for its TriVice (triage, referral and advice) mobile app.
TriVice streamlines doctor-patient care by managing acute referrals to specialist clinicians routed through its mobile app. The app captures patient demographics, details of the injury/condition and facilitates the sharing of clinical photographs and images. The app triages and enables sending of Advise and Guidance with an aim to reduce avoidable referrals. Additionally, the app enables real-time notification and communication with referring clinicians as well as integration into existing hospital systems. TriVice makes the referral process easier, smoother, seamless and with better documentation. The app’s goal is to advance the digital-first strategy of the National Health Service (NHS), the publicly funded healthcare system in England.
An automated and self-defending cloud-based solution, Verimatrix App Shield provides Capri Healthcare with peace of mind that staff and patient experiences with its TriVice mobile app are protected against numerous nefarious activities. Though a zero-code (no programming required), SaaS approach, App Shield harden apps and helps prevent hacking attacks such as reverse engineering, application repackaging, dynamic modification, man-in-the-middle attacks and much more.
“Capri Healthcare is an organization driven by the vision of turning the NHS digital-first strategy into reality by bringing digital innovation into the working of healthcare providers,” said Krishna Thakur and Valleesh Athreya, founders at Capri Healthcare. “We are dedicated to using technology to improve care, identifying patient conditions earlier, reducing backlog, digitizing processes and eliminating wasteful tasks. We realize that all of that is only possible if we do so by deploying solutions that are secure and trusted by all. Verimatrix answers that need by quickly and cost-effectively adding enterprise-quality threat defense to our TriVice mobile app.”
“At Verimatrix, we are proud to support innovative organizations such as Capri Healthcare that develop, deploy and accelerate the adoption of breakthrough mobile health experiences that strive to make the world a healthier, better place,” said Asaf Ashkenazi , Chief Operating Officer and President at Verimatrix. “We are especially pleased to work with healthcare innovators like Capri Healthcare, as practitioners and patients alike see privacy and security as a standard expectation, especially as new digital processes are established and adopted. This announcement proves again that Verimatrix’s threat defense solutions are essential for the global healthcare market that is rapidly adopting mobile technologies.”
About Capri Healthcare
Capri Healthcare is an organization driven by the vision of turning the NHS Digital First strategy into reality by bringing digital innovation to healthcare providers. Leading healthcare organizations into the digital era by redesigning and developing patient-centric online systems (web & mobile), Capri Healthcare helps significantly reduce the burden on staff as well as the NHS. The company prides itself in offering a range of technology-driven innovative solutions that drive the healthcare industry’s digital agenda. Visit www.caprihealthcare.co.uk
.
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit www.verimatrix.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005504/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
